Now reading Entry 102 / 102 Last revised Jan 22, 2026 28 sources Methodology →
A specimen of the Other drawer Drawer G · Other

Zelenectide Pevedotin

Investigational

A first-in-class Bicycle Drug Conjugate (BDC) targeting Nectin-4 for solid tumors, developed by Bicycle Therapeutics. In the Duravelo-1 Phase 1/2 dose-escalation study it produced a 38% objective response rate (8/21) in urothelial carcinoma using a novel bicyclic peptide platform much smaller than traditional antibody-drug conjugates. Phase 2/3 Duravelo-2 registrational trial ongoing.

BT8009 · Bicycle Drug Conjugate BT8009

Research evidence
Moderate

22 human studies

Preclinical
21%
Clinical
79%

Based on 28 cited sources

Evidence Score52/100
Early / limited
Research Depth42/100
Mechanism79/100
Plausibility85/100
Global Coverage46/100
Community Experience0/100
Effectiveness57/100

clinically demonstrated · low confidence

Demonstrated effect magnitude — not a recommendation or safety claim.

Research Depth 42: best human tier is a single uncontrolled open-label Phase 1/2 dose-escalation (Duravelo-1, n=49; 41197088) so 1A=15; no randomization/blinding caps 1B=6; total human N<50 gives 1C=3; direct population/route/outcome (UC, IV, ORR/DoR) 1D=12; substantial single-sponsor preclinical program across models incl. rat/NHP PK (36112771) 1E=6. Mechanism 79: Nectin-4 named target with sub-nM binding plus functional endocytosis/payload-delivery confirmation 2A=30; near-full pathway binding->endocytosis->linker cleavage->MMAE->tubulin->mitotic arrest->apoptosis 2B=26; dose-response across preclinical models and clinical escalation (2.5-10 mg/m2) 2C=14; confirmed in in-vivo mammalian models 2D=9. Plausibility 85: mechanism->surrogate(ORR)->emerging clinical(DoR) chain 3A=30; fully coherent with validated Nectin-4 biology 3B=24; same-class analogy strong (enfortumab vedotin approved on Nectin-4) 3C=18; tightly scoped Nectin-4-restricted claim 3D=13. Global Coverage 46: clinical evidence concentrated in one sponsor (Bicycle Therapeutics) program but multinational trial sites 4A=12; 4-6 countries (US/CA/FR/ES/IT/UK) 4B=16; ~28 sources with independent reviews (40401457, 41164107) 4C=13; FDA Fast Track + trial registration, not yet approved, 4D=5. Community Experience 0: investigational clinical-trial-only oncology agent with no documented real-world/community use. Effectiveness basis clinical (low confidence): 38% ORR (8/21) in heavily pretreated UC with 11.1mo median DoR is a moderate-large effect exceeding a meaningful response threshold in a refractory setting (E1=18, E2=15), tumor-response/DoR outcomes with OS immature (E3=10), superior to placebo expectation on a clinical outcome but no head-to-head and uncontrolled single-arm data (E4=14); Phase 2/3 Duravelo-2 ongoing.

Scored June 2026 How we rate →
~
Evidence Level
moderate
Not approved for human use by any regulatory agency
Limited human clinical trial data
Consult a healthcare provider before use
Not FDA Approved WADA Prohibited
Identity
SCALE · 1:1 N-TERMINUS C-TERMINUS 15 AA · ~3,500 Da
Also Known As
BT8009 • Bicycle Drug Conjugate BT8009
Class
Bicyclic Peptide-Drug Conjugate
Length
15 amino acids
Mol. weight
~3,500 Da
Sequence
Proprietary constrained bicyclic peptide
Molecular Structure
C
X
X
X
C
X
X
X
C
X
X
X
X
X
X
Hydrophobic
Polar
Positive
Negative

The mechanism of zelenectide pevedotin is well-characterized through extensive preclinical and clinical research. Human clinical data supports the proposed mechanism.

How It Works (Simplified)

Zelenectide pevedotin functions as a precision “smart missile” targeting cancer cells:

Target Recognition

Bicyclic peptide binds Nectin-4 protein overexpressed on cancer cells (60-90% in urothelial cancer) with sub-nanomolar affinity.

Rapid Penetration

Small size (~2-3 kDa vs ~150 kDa for ADCs) enables fast, deep tumor penetration within hours rather than days.

Payload Delivery

After internalization, lysosomal enzymes cleave the linker releasing MMAE cytotoxin inside the cancer cell.

Cell Death

MMAE blocks tubulin polymerization, arrests mitosis, and triggers apoptosis. Bystander effect kills neighboring tumor cells.

Key Research: Rigby M, Bennett G et al. (2022) characterized BT8009 as a small hydrophilic Bicycle Toxin Conjugate that rapidly diffuses through tissue to penetrate Nectin-4-expressing tumors, with antitumor activity superior or equivalent to an enfortumab vedotin analog in preclinical models. PMID:36112771

Important Limitations

  • Investigational drug not yet approved by FDA or other regulatory agencies
  • Available only through clinical trial enrollment (NCT04561362, NCT06225596)
  • No head-to-head trials vs enfortumab vedotin completed
  • Long-term survival data still maturing (median follow-up ~2-3 years)
  • Optimal sequencing with other Nectin-4 targeting agents unknown
i. Nectin-4 Targeting and Internalization · Primary Mechanism
Zelenectide pevedotin (IV)Rapid tumor distribution (small size)Bicyclic peptide binds Nectin-4 (sub-nM affinity)Receptor-mediated endocytosisLysosomal trafficking
ii. MMAE Release and Cytotoxicity · Payload Mechanism
Cathepsin B cleaves valine-citrulline linkerFree MMAE releasedMMAE binds tubulinBlocks polymerizationMitotic arrestApoptosis (cell death)
Mechanism Nectin-4 binding and receptor-mediated endocytosis delivering MMAE payload
Established 22 direct studies
Benefit shown to induce tumor cell death in Nectin-4 expressing cancers
Evidence Level
High
22 Human
6 Animal
8 In Vitro
Mechanism Rapid tumor penetration due to small molecular size (~40x smaller than ADCs)
Established 8 direct studies
Benefit shown to achieve faster and deeper tumor tissue distribution
Evidence Level
Moderate
5 Human
6 Animal
4 In Vitro
Mechanism MMAE release and tubulin polymerization inhibition causing mitotic arrest
Established 15 direct studies
Benefit shown to induce apoptosis in rapidly dividing tumor cells
Evidence Level
High
18 Human
6 Animal
10 In Vitro
Mechanism Fast systemic clearance reducing off-target tissue exposure
Supported 10 direct studies
Benefit appears to improve tolerability compared to traditional ADCs
Evidence Level
Moderate
15 Human
4 Animal
Mechanism Confidence
Established
Supported
Emerging
Evidence Level
High
Moderate
Low
Very Low
Phase 01 1
Day 1

IV infusion administered over 30-60 minutes. Rapid distribution to Nectin-4-expressing tumors due to small molecular size. Plasma half-life of 3-6 hours.

NCT04561362
Phase 02 2
Week 1-4

Weekly dosing at 5.0 mg/m2 RP2D. Initial tumor assessment typically at 8-12 weeks per clinical trial protocols. Early responders may show tumor marker changes.

NCT04561362
Phase 03 3
Week 8-12

First radiographic response assessment. In the Duravelo-1 Phase 1/2 study, responses were observed across this timeframe, with a 48% clinical benefit rate across tumor types (57% in urothelial carcinoma).

PMID:41197088
Phase 04 4
Month 3+

Median duration of response 11.1 months in responders. Continued dosing until progression or unacceptable toxicity.

PMID:41197088

Research-based observations

This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.

Good Signs (6 indicators)
Administered only in clinical trial settings under medical supervision
Enrolled in registered clinical trial (NCT04561362 or NCT06225596)
Proper screening for Nectin-4 expression if required by protocol
Baseline neuropathy assessment completed
Informed consent obtained with full understanding of investigational status
Access to experienced oncology care team
Warning Signs (4 indicators)
Pre-existing peripheral neuropathy (Grade 1-2) requiring close monitoring
Prior enfortumab vedotin exposure (may still respond but monitor closely)
History of infusion reactions requiring premedication protocol
Moderate renal impairment requiring dose consideration
Bad Signs (5 indicators)
Attempting to obtain outside of clinical trial (not approved)
Severe pre-existing peripheral neuropathy (Grade 3+)
Known hypersensitivity to MMAE or bicyclic peptides
Pregnancy or planning pregnancy (teratogenic potential)
No access to appropriate oncology monitoring and supportive care
Positive quality indicator
Requires evaluation
Potential quality issue

For Research Evaluation Only

These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.

Synergistic
Compatible
Caution
Avoid

Pembrolizumab

Compatible
Compatible

Combination studies planned. Checkpoint inhibitors may complement BDC mechanism. Preclinical data suggests enhanced efficacy with PD-1 inhibition.

Sacituzumab-Govitecan

Compatible
Compatible

Different targets (Nectin-4 vs Trop-2) and payloads (MMAE vs SN-38). Sequential use in urothelial cancer may be feasible based on distinct mechanisms.

Enfortumab-Vedotin

Caution
Caution

Both target Nectin-4 with MMAE payload. Sequential use may be possible as BT8009 shows activity post-EV (~30-35% ORR). No concurrent use data available.

Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.

28 Sources 22 Human 6 Preclinical

Key Studies Cited

RCT Baldini C et al. 2025
PMID:41197088
Animal Rigby M et al. 2022
PMID:36112771
Review Cigliola A et al. 2025
PMID:40401457

Full reference list available on request. All citations link to PubMed for verification.

This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.

For complete methodology details, see our Methodology page.

Important Disclaimer

This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.

Get Research Alerts

New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.

No spam. Unsubscribe anytime.

Compare Zelenectide Pevedotin

Related Peptides

Other

225Ac-DOTA-LM3

Actinium-225-DOTA-LM3 · 225Ac-DOTA-JR11 · Alpha-PRRT +1

An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.

See dossier
Other

Bronchogen

AEDL · Ala-Glu-Asp-Leu · Bronchial tetrapeptide +1

A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.

See dossier
Other

BT5528

Bicycle Toxin Conjugate 5528 · EphA2-BTC

A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. The first-in-human Phase I (45 patients, advanced solid tumors) reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose; expansion ongoing.

See dossier
Other

Cardiogen

AED · Ala-Glu-Asp · Cardiac tripeptide

A synthetic tripeptide (Ala-Glu-Asp, AED) developed by Russian scientist Vladimir Khavinson and marketed as a cardiac "bioregulator." Despite that marketing, no PubMed-indexed study has examined AED in heart, cardiomyocyte, or myocardial tissue. The only published AED research is in vitro and non-cardiac — anti-aging gene-expression effects in cultured stem cells, fibroblasts, kidney and immune cells. No human or animal data and no regulatory approval anywhere.

See dossier
Other

Chelohart

Heart cytamin · Cardiac peptide supplement · A-7 heart peptides

A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.

See dossier
Other

Chonluten

EDG-GI · Glu-Asp-Gly (GI) · GI tract tripeptide +1

A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.

See dossier